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Abstract
Prostate cancer (PC) is one of the leading causes of death in males. Available treatments often lead to the appearance
of chemoresistant foci and metastases, with mechanisms still partially unknown. Within tumour mass, autophagy may
promote cell survival by enhancing cancer cells tolerability to different cell stresses, like hypoxia, starvation or those
triggered by chemotherapic agents. Because of its connection with the apoptotic pathways, autophagy has been
differentially implicated, either as prodeath or prosurvival factor, in the appearance of more aggressive tumours. Here,
in three PC cells (LNCaP, PC3, and DU145), we tested how different autophagy inducers modulate docetaxel-induced
apoptosis. We selected the mTOR-independent disaccharide trehalose and the mTOR-dependent macrolide lactone
rapamycin autophagy inducers. In castration-resistant PC (CRPC) PC3 cells, trehalose speciﬁcally prevented intrinsic
apoptosis in docetaxel-treated cells. Trehalose reduced the release of cytochrome c triggered by docetaxel and the
formation of aberrant mitochondria, possibly by enhancing the turnover of damaged mitochondria via autophagy
(mitophagy). In fact, trehalose increased LC3 and p62 expression, LC3-II and p62 (p62 bodies) accumulation and the
induction of LC3 puncta. In docetaxel-treated cells, trehalose, but not rapamycin, determined a perinuclear
mitochondrial aggregation (mito-aggresomes), and mitochondria speciﬁcally colocalized with LC3 and p62-positive
autophagosomes. In PC3 cells, rapamycin retained its ability to activate autophagy without evidences of mitophagy
even in presence of docetaxel. Interestingly, these results were replicated in LNCaP cells, whereas trehalose and
rapamycin did not modify the response to docetaxel in the ATG5-deﬁcient (autophagy resistant) DU145 cells.
Therefore, autophagy is involved to alter the response to chemotherapy in combination therapies and the response
may be inﬂuenced by the different autophagic pathways utilized and by the type of cancer cells.
Introduction
In men, prostate cancer (PC) is the second most com-
mon form of cancer and one of the leading causes of
cancer death. PC is initially hormone-dependent and
androgen deprivation therapy (ADT) is the preferred
treatment also used for relapsed and metastatic PC
patients1. During ADT many patients develop metastatic
castration-resistant PC (CRPC)2–4, and they are treated
with chemotherapeutic agent, like docetaxel5–7 which,
despite clinical beneﬁts, may induce docetaxel-resistance8,
possibly due to an aberrant autophagy response9.
Macroautophagy (hereafter autophagy) is a conserved
degradative pathway in which proteins or cytoplasmic
components are engulfed into autophagosomes that fuse
with lysosomes, for their degradation10. Generally,
autophagy promotes cell survival in response to starvation
or other cell stresses. Autophagy has been implicated in
the aetiology of cancer, acting as either prodeath or pro-
survival factor depending on type and stage of cancer
considered. Oncosuppressive autophagy functions relate
to decreased accumulation of genetic and genomic defects
typical of malignant transformation. Indeed, an inefﬁcient
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autophagy allows tumorigenesis and characterizes the
early stage of cancer. Conversely, increased autophagy
characterizes existing advanced malignancies correlating
with an invasive/metastatic phenotype. Therefore,
autophagy defects might facilitate cancer transformation
of healthy cells but enhance autophagic responses to
support cancer cells survival, proliferation and growth in
adverse microenvironmental conditions11,12. Also during
cancer treatment autophagy has a paradoxical effect
related to contest, type, and stage of tumours. Autophagy
may enhance cancer therapy efﬁcacy through cell death
promotion by itself (cell death type II) or in cooperation
with apoptosis (cell death type I)13–15, and thus it is
crucial to understand how autophagy regulates or is
regulated by apoptosis.
Acting as a defensive stress mechanism, autophagy is also
involved in chemoresistance9,16–18, by enhancing cell stress
tolerance. Moreover, autophagy by removing damaged
mitochondria (mitophagy) prevents chemotherapy-induced
apoptosis19,20, since mitophagy increases apoptotic resis-
tance21,22. Thus, the response to chemotherapy (docetaxel)
may be modulated by autophagy inducers in CRPC cell
lines.
The natural disaccharide trehalose is a potent autop-
hagy inducer23 used to improve the clearance of misfolded
proteins causing proteotoxic cell stresses in cell and ani-
mal models of neurodegenerative diseases24–30. However,
it is unknown whether trehalose can activate autophagy in
CRPC cells. The macrolide lactone rapamycin is another
autophagy activator. While trehalose does not involve the
mammalian target of rapamycin (mTOR)31,32, rapamycin
speciﬁcally inhibits the mTOR pathway. The mTOR sig-
nalling represses autophagy and regulates cell growth,
proliferation, survival, angiogenesis33–36 and is upregu-
lated in almost 50% of PC37. In PC cells, rapamycin exerts
cytotoxic effects38 and enhances radio- and chemio-
sensitivity39–41.
In this study, we investigated the effects of trehalose
and rapamycin on the docetaxel response in classical PC
cell lines (LNCaP, PC3 and DU145) demonstrating that
these two autophagy activators exert very different roles
on docetaxel-sensitivity. Trehalose prevents intrinsic
apoptosis induced by docetaxel in PC cells promoting
cytoprotective mitophagy. Conversely, rapamycin
induces a type II cell death, that does not alter the
ability of docetaxel to trigger apoptotic response, but
rather enhances the cytotoxic effect of chemotherapy.
Thus, depending on the type of autophagy activation,
docetaxel-induced toxicity may be differentially modu-
lated in CRPC cells. These observations are crucial to
design combination therapies to prevent cancer
resistance and enhance the effects of anticancer
therapies.
Results
Here, we analysed how autophagy modulates docetaxel-
sensitivity of CRPC cells, using two different known
autophagy-inducing agents and we evaluated the PC3
cells autophagy response.
Trehalose induces autophagy in PC3 cells
Trehalose effect on cell viability was tested in PC3 cells
(20–100mM) without observing modiﬁcations (Fig. 1a).
Based on the literature, 100mM of trehalose was selected
to activate autophagy31,42 which was analysed evaluating
nuclear translocation of transcription factor EB (TFEB)
(one of the master regulators of autophagy that induces
the expression of several autophagy and lysosome-related
genes)43, mRNA expression and protein levels and dis-
tribution of two classical autophagy markers:
microtubule-associated protein1A/1B-light chain 3 (LC3)
and the sequestosome-1 (SQSTM1) or p6244. At this
concentration, in PC3 cells trehalose induced nuclear
translocation of TFEB (Fig. 1b) and enhanced LC3 mRNA
expression after 48 and 72 h (Fig. 1c), suggesting that
autophagy was activated. During autophagy activation,
LC3 is converted from its diffuse cytoplasmic LC3-I form
to LC3-II, the lipidated form recruited to the nascent
autophagosomes membrane. Therefore, we analysed the
LC3-II/LC3-I ratio in western blot (WB) and its intra-
cellular distribution (from diffuse to punctate) by immu-
noﬂuorescence microscopy (IF). We found that trehalose
increased LC3-II levels (Fig. 1d), and induced LC3 puncta
formation (Fig. 1e). Since autophagosome-anchored LC3-
II is cleared from cells by autophagy, we quantiﬁed
trehalose-mediated activation of autophagy after autop-
hagy ﬂux inhibition with 3-methyladenine (3-MA) added
1 h before trehalose treatment. As shown in Fig. 1f, the
levels of trehalose-induced LC3-II were greatly reduced by
3-MA. The effect of trehalose on autophagy was con-
ﬁrmed to be speciﬁc by silencing the ATG5 gene45, whose
protein product is required to activate autophagy (Fig. 1g).
Then, we inhibited the clearance of autophagosomes and
amphisomes with chloroquine (CQ) and NH4Cl (two
lysosomal lumen alkalizers which neutralize the acidic pH
inactivating lysosomal degrading enzymes)46. As shown in
Fig. 1h, both CQ and NH4Cl increased LC3-II levels
induced by trehalose suggesting that in PC3 cells treha-
lose induces and sustains a normal autophagy ﬂux.
Autophagic ﬂux activation was also analysed by the
overexpression of GFP-LC3 reporter vector with or
without autophagosome-lysosome fusion inhibition (Fig.
S1a)47.
Next, we analysed the autophagy adaptor p62, which
binds polyubiquitinated proteins engulﬁng them into
autophagosomes44. As reported for LC3, p62 expression is
upregulated during autophagy activation and it is
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degraded by autophago-lysosomes, but when the autop-
hagic ﬂux is insufﬁcient or blocked p62 accumulates into
liquid droplets called “p62 bodies”. p62 is upregulated in
different cancer types, and in CRPC correlates with
tumour progression and resistance to therapies48,49. In
PC3 cells we found that trehalose increases p62 mRNA
and protein levels both at 48 and 72 h after treatment
(Fig. 1i, j). IF analysis showed that trehalose-treated cells
contain several “p62 bodies” while p62 has a diffuse
cytosolic localization in control cells (Fig. 1k). Trehalose
cotreatment with CQ or NH4Cl increased p62 levels
compared to trehalose-treated cells (Fig. 1l). Moreover,
Fig. 1 (See legend on next page.)
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trehalose treatment increased the clearance of an elon-
gated polyQ containing protein (Fig. S1b) indicating that
autophagic ﬂux is active. In fact, it normally accumulates
as insoluble species in the cells as consequence of
autophagy impairment28,30. Thus, trehalose induces
autophagy in PC3 cells and LC3 and p62 protein levels
heightened because their synthesis is greater than their
degradation.
Rapamycin induces autophagy in PC3 cells
Next, we compared the mTOR-independent trehalose-
induced autophagy to that triggered via the mTOR inhi-
bitor rapamycin. Rapamycin becomes cytotoxic at dose
higher than 50 nM (Fig. 2a). We analysed rapamycin-
induced autophagy activation (doses from 10 to 100 nM)
and selected the best concentration of 100 nM (Fig. 2b),
which is usually used in PC studies to trigger autop-
hagy50–52. At this dose, in PC3 cells rapamycin induced
nuclear translocation of TFEB (Fig. 2c) and increased LC3
mRNA only after 72 h (Fig. 2d) and did not affect the
LC3-II levels and the LC3-II/LC3-I ratio (Fig. 2e). Con-
versely, both parameters were increased after cotreatment
with CQ and NH4Cl indicating that rapamycin induces
the autophagic ﬂux in PC3 cells (Fig. 2f). LC3 distribution
conﬁrmed a punctate staining in rapamycin-treated cells
(with or without CQ) indicative of LC3 accumulation into
autophagosomes (Fig. 2g), suggesting an elevated LC3
turnover upon rapamycin treatment in basal condition. In
parallel, rapamycin induced p62 mRNA expression only at
48 h (Fig. 2h), while p62 protein levels and distribution
showed a reduction of p62 protein and the appearance of
p62 bodies (Fig. 2i, j). CQ or NH4Cl treatments coun-
teracted rapamycin-induced p62 reduction (Fig. 2k).
Therefore, rapamycin activates autophagy and autophagic
ﬂux rapidly degrades LC3 and p62 via autophago-
lysosomes.
We also evaluated the effect of trehalose and rapamycin
in another classical model of PC cells, LNCaP cells, and
we found a complete overlap between the two cell models
on trehalose and rapamycin cell viability (Fig. 3a) and
autophagy induction (Fig. 3b, c). Next, we tested whether
these effects require a functional autophagic activation
using DU145 cells lacking expression of functional
ATG545. In DU145 cells trehalose and rapamycin exert
the same effect as in the PC3 and LNCaP cells on cell
viability (Fig. 3d), but as expected autophagy is not acti-
vated by trehalose and rapamycin (Fig. 3e, f).
Docetaxel induces apoptosis, autophagy, and
mitochondrial ﬁssion in PC3 cells
Docetaxel is a widely used antineoplastic agent in PC53.
Unfortunately, patients develop docetaxel-resistance
afterwards. Multiple molecular mechanisms contribute
to this chemoresistance including apoptosis inhibition8.
We analysed whether docetaxel-induced cell death might
be mediated by autophagy. In PC3 cells, docetaxel
induced a dose-dependent toxicity from 10 to 100 nM
(Fig. 4a). Docetaxel-induced apoptosis was analysed
evaluating caspase-3 cleavage. WB analysis showed that
docetaxel (20 nM) induced caspase-3 cleavage after 48
and 72 h (Fig. 4b) conﬁrming that, in PC3 cells, docetaxel
induces apoptotic cell death. We also analysed whether
(see ﬁgure on previous page)
Fig. 1 Trehalose induces autophagy in PC3 cells. a MTT viability assay was performed on PC3 cells treated for 48 h with 20, 50 or 100mM
trehalose. Six independent biological samples for each condition were analysed (n= 6), bar graph represents the mean relative cell viability ± SD.
Statistical analysis was performed using Student’s t test. b TFEB localization was carried out by IF after treatment with 100mM trehalose for 24 h.
Nuclei were stained with DAPI. Scale bar, 20 μm. c LC3 mRNA expression was analysed by RT-qPCR after treatment with 100 mM trehalose for
48 or 72 h. Data were normalized to the amount of RplP0 mRNA. Bar graph represents the mean of four independent biological samples (n= 4) ± SD
(*p < 0.01 vs. control 48 h, **p < 0.01 vs. control 72 h; Student’s t test). d Autophagy was analysed by quantiﬁcation of LC3-II/LC3-I ratio by WB analysis
of PC3 cells treated for 24, 48 or 72 h with 100mM trehalose. e LC3 puncta was carried out by IF after treatment with 100mM trehalose for 48 h.
Nuclei were stained with DAPI. Scale bar, 20 μm. f PC3 cells pretreated with or without 1 mM 3-MA for 1 h were exposed to 100 mM trehalose
for additional 48 h. WB analysis of LC3 was carried out. Relative optical density of LC3II/I was quantiﬁed by ImageJ software. Bar graph represents
mean ± SD calculated from three independent experiments. Statistical analysis was performed by one-way ANOVA followed by Bonferroni post-test
(*p < 0.05). g PC3 cells were transfected with 50 nM negative control (NC) or ATG5 siRNA and WB of ATG5 was performed. Quantiﬁcation of LC3 in
PC3 cells transfected and treated 48 h with 100mM trehalose was carried out. h PC3 cells were treated with 100mM trehalose for 48 h and with 10
μM CQ or 2.5 mM NH4Cl for the last 24 h before their collection. WB shows LC3 protein levels. Relative optical density of LC3II/I was determined
by ImageJ software. Bar graph represents mean ± SD calculated from three independent experiments. Statistical analysis was performed by one-way
ANOVA followed by Bonferroni post-test (*p < 0.05). i p62 mRNA expression levels were detected by RT-qPCR after treatment with 100 mM trehalose
for 48 or 72 h. Data were normalized to the amount of RplP0 mRNA. Bar graph represents the mean of four biological independent samples (n= 4) ±
SD (*p < 0.05 vs. control 48 h, **p < 0.01 vs. control 72 h; #p < 0.05 vs. control 48 h, Student’s t test). j PC3 cells were treated with 100mM trehalose for
48 or 72 h. Twenty micrograms of protein extract was analysed by WB against p62. The quantiﬁcation results were calculated over three individual
experiments. Statistical analysis was performed by one-way ANOVA with Bonferroni post-test (*p < 0.05 vs. control 48 h, **p < 0.05 vs. control 72 h;
#p < 0.05 vs. control 48 h). k p62 localization was analysed by IF with anti-p62 antibody followed by FITC-conjugated secondary antibody in cells
treated with 100mM trehalose for 48 h. Nuclei were stained with DAPI. Scale bar, 20 μm. l PC3 cells were treated with 100 mM trehalose for 48 h
and with 10 μM CQ or 2.5 mM NH4Cl for the last 24 h before their collection. p62 levels were analysed by WB. Bar graph represents quantiﬁcation
mean ± SD calculated from three independent experiments. Statistical analysis was performed by one-way ANOVA with Bonferroni post-test
(*p < 0.05)
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docetaxel induces autophagy in PC3 cells and whether
autophagy modulates docetaxel-induced apoptosis.
Notably, docetaxel increased LC3 expression (Fig. 4c),
LC3-II/LC3-I ratio after 48 and 72 h (Fig. 4d), and mod-
iﬁed LC3 distribution from diffuse to punctate staining
(Fig. 4e). p62 mRNA was increased after 48 and 72 h of
docetaxel treatment (Fig. 4f), while no changes were
found in p62 protein levels (Fig. 4g), which accumulated
into p62 bodies (Fig. 4h). To determine how autophagy
mediates docetaxel-induced toxicity, we cotreated PC3
cells with docetaxel and 3-MA and we found that 3-MA
has no effect on docetaxel-cytotoxicity (Fig. 4i).
Since in PC3 cells docetaxel toxicity is exerted via
apoptosis, we tested how the intrinsic apoptotic pathway
is involved by evaluating mitochondrial morphology and
the possible modulation by autophagy. Indeed, mito-
chondria dynamics, ﬁssion and fusion, exert paradoxical
roles in cell survival and death54. Mitochondrial ﬁssion
Fig. 2 (See legend on next page.)
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generates morphologically and functionally distinct
mitochondria and often occurs in the apoptotic event55.
In PC3 cells, we evaluated whether this is a determinant
event in chemo-sensitivity. In live ﬂuorescence micro-
scopy we observed that pDsred2-mito labelled mito-
chondria underwent ﬁssion after docetaxel treatment for
48 h, conﬁrming that this process could mediate
docetaxel-induced cell death. Trehalose alone partially
induced mitochondrial ﬁssion, while docetaxel and tre-
halose administered together induced mitochondrial
aggregation. Rapamycin alone induced mitochondrial
fragmentation, which remained unchanged after doc-
etaxel treatment (Fig. 4j).
Trehalose and rapamycin differently modify mitochondria/
autophagosomes colocalization in docetaxel-treated PC3
cells
Since trehalose, rapamycin and docetaxel, either used
alone or in combination, induce mitochondrial ﬁssion, we
tested a possible mitophagy activation by analysing whe-
ther autophagosomes colocalize with fragmented mito-
chondria. In fact, mitophagy, by clearing damaged
mitochondria, is critical for cancer cells survival under
different stresses56, possibly acting by reducing apopto-
sis19,57. IF analysis and confocal microscopy were
used to detect mitophagy activation evaluating LC3 or
p62 colocalization with MitoTracker Orange-stained
mitochondria58.
In PC3 cells a clear colocalization of LC3-labelled
autophagosomes and mitochondria was found after
trehalose treatment, which was further conﬁrmed by
cotreatment with docetaxel. Docetaxel alone, rapamycin
and their cotreatments did not induce autophagosomes
and mitochondria colocalization, and the two organelles
remained conﬁned into different cytoplasm regions. As
expected, docetaxel treatment induced nuclear fragmen-
tation, which was not modiﬁed by cotreatment with
rapamycin, while trehalose completely reverted the
docetaxel-induced phenotype at nuclear levels (Fig. 5a and
Fig. S2). Thus, trehalose has a potent protective activity
against docetaxel-induced apoptosis. p62 was also found
colocalized with mitochondria both in trehalose- or tre-
halose−docetaxel-treated cells. p62/mitochondria colo-
calization was absent in rapamycin- or docetaxel-treated
(alone or in combination) cells (Fig. 5b and Fig. S3). Thus,
the apoptotic stress induced by docetaxel alters mito-
chondria morphology and distribution, but trehalose
eliminates damaged mitochondria by mitophagy, while
rapamycin induces a nonselective autophagy that does not
involve mitophagy.
Trehalose and rapamycin differently modify mitochondria/
lysosomes colocalization in docetaxel-treated PC3 cells
To further evaluate these differential effects of trehalose
and rapamycin on mitochondria clearance via autophagy,
we evaluated mitochondria (stained with MitoTracker
Orange) and lysosomes (stained with LysoTracker Green)
distribution in PC3 cells and we found that trehalose
alone or in the presence of docetaxel induced mito-
chondria and lysosomes colocalization (Fig. 6), conﬁrming
(see ﬁgure on previous page)
Fig. 2 Rapamycin induces autophagy in PC3 cells. a PC3 cells were treated for 48 h with 10, 50 or 100 nM rapamycin. MTT viability assay was
performed. Data are mean ± SD of six independent biological samples (n= 6). Statistical analysis was performed using Student’s t test (*p < 0.05 vs.
control). Each experiment was repeated three times. b WB analysis of LC3 was performed with lysate of cells treated for 48 h with different doses of
rapamycin (10, 50, 100 nM). Fifteen micrograms of protein extract was loaded in SDS-gel electrophoresis. Detection of autophagy was analysed by
quantiﬁcation of LC3-II/LC3-I ratio. Relative optical density was determined by ImageJ software. Experiments were performed independently three
times and a representative blot is shown. c TFEB localization was carried out by IF after treatment with 100 nM rapamycin for 48 h. Nuclei were
stained with DAPI. Scale bar, 20 μm. d LC3 mRNA expression levels were analysed by RT-qPCR after treatment with 100 nM rapamycin for 48 or 72 h.
Data were normalized to the amount of RplP0 mRNA. Data are mean ± SD of four independent biological samples (n= 4). Statistical analysis was
performed using Student’s t test (*p < 0.05 vs. control 72 h). eWB analysis of LC3 was performed with lysate of cells treated for 24, 48 or 72 h with 100
nM rapamycin. Detection of autophagy was analysed by quantiﬁcation of LC3-II/LC3-I ratio. Relative optical density was determined by ImageJ
software. Experiments were performed independently three times and a representative blot is shown. f Cells were treated with 100 nM rapamycin for
48 h and CQ (10 μM) or NH4Cl (2.5 mM or 5 mM) for the last 24 h before their collection. LC3 levels were analysed by WB and relative optical density
of LC3II/I was determined by ImageJ software. Experiments were performed independently three times and a representative blot is shown. g LC3
puncta were analysed by IF utilizing anti-LC3 antibody followed by FITC-conjugated secondary antibody. Cells were treated with 100 nM rapamycin
alone for 48 h or in combination with 10 μM CQ for the last 24 h. Nuclei were stained with DAPI. Scale bar, 20 μm. h p62 mRNA expression levels were
detected by RT-qPCR after treatment with 100 nM rapamycin for 48 or 72 h. Data were normalized to the amount of RplP0 mRNA. Data are mean ±
SD of four independent biological samples (n= 4). Statistical analysis was performed using Student’s t test (*p < 0.01 vs. control 48 h, ##p < 0.01 vs.
control 48 h). i Cells were treated with 100 nM rapamycin for 48 or 72 h. Twenty micrograms of protein extract was analysed by WB. The
quantiﬁcation results were calculated from three independent experiments. Statistical analysis was performed using one-way ANOVA followed by
Bonferroni post-test (*p < 0.05 vs. control 48 h, **p < 0.05 vs. control 72 h). j p62 was analysed by IF using anti-p62 antibody followed by FITC-
conjugated secondary antibody in cells treated with 100 nM rapamycin for 48 h. Nuclei were stained with DAPI. Scale bar, 20 μm. k Cells were treated
with 100 nM rapamycin for 48 h and 10 μM CQ or 2.5 mM NH4Cl for the last 24 h before their collection. p62 levels were analysed by WB. Bands
relative optical density was determined by ImageJ software. The quantiﬁcation results were calculated from three independent experiments.
Statistical analysis was performed by one-way ANOVA with Bonferroni post-test (*p < 0.05 vs. control)
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mitophagy activation. Conversely, controls, docetaxel
or rapamycin (with or without docetaxel) treated cells
had a clear separation between these cytoplasmic
organelles. Furthermore, rapamycin-treated cells, with
or without docetaxel, showed ﬂattened morphology
and large vacuoles typical of a complete autophagic
process.
Trehalose and rapamycin different counteract docetaxel-
induced apoptosis in PC3 cells
To prove that the trehalose-induced mitophagy corre-
lates with apoptotic capability of cancer cells, we analysed
the impact of the intrinsic apoptotic pathway and its
correlation with mitochondria dynamics, analysing the
effect of trehalose and rapamycin on docetaxel-induced
Fig. 3 (See legend on next page.)
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cytochrome c release, activation of caspase-9, caspase-3
and the cleavage of PARP. Cytochrome c colocalization
with MitoTracker Orange-stained mitochondria was
evaluated by IF microscopy in PC3 cells treated with
docetaxel and trehalose alone or in combination. In basal
condition, or in cells treated only with trehalose, cyto-
chrome c and MitoTracker colocalized docetaxel-induced
cytochrome c release from mitochondria (Fig. 7a), while
trehalose completely reverted the cytochrome c release
from mitochondria to cytoplasm induced by docetaxel
(Fig. 7a). Thus, trehalose likely counteracts docetaxel-
induced apoptosis, possibly by promoting the clearance of
damaged mitochondria through mitophagy and by
increasing resistance to apoptotic death. Analysing cas-
pase-9, caspase-3, PARP and their active cleaved forms
(Fig. 7b), we found that docetaxel triggered intrinsic
apoptosis pathway via cleavage of caspase-9, 3 and PARP,
while trehalose was inactive on these parameters, but fully
counteracted the proapoptotic action of docetaxel on all
proteins tested. Again, in basal condition, or in cells
treated only with rapamycin, cytochrome c and Mito-
Tracker colocalized, suggesting that rapamycin is unable
to induce cytochrome c mitochondrial release, or to
activate caspase-9, 3 and PARP and was unable to coun-
teract the docetaxel-induced cytochrome c release from
mitochondria (Fig. 7c) and the docetaxel ability to trigger
apoptosis via caspases (Fig. 7d). The effects of trehalose
and rapamycin on the docetaxel-induced cell death were
also analysed by PI and annexin V double staining using
ﬂow cytometry (Fig. 7e). Docetaxel treatment increased
the number of apoptotic PC3 cells by about 40% (from
9.46 to 13.64%) and trehalose cotreatment reduced
apoptotic PC3 cells by about 30% (from 13.64 to 9.48%)
and drastically reduced early apoptotic PC3 cells (50%
from 10.86 to 5.73%). As expected rapamycin cotreatment
did not alter apoptotic PC3 cells induced by rapamycin
alone (10.75 compared to 10.11) even if it increased
necrotic PC3 cells. Moreover, in high-dose docetaxel-
treated PC3 cells trehalose reduced late apoptotic cells by
about 45% (from 6.15 to 2.75%) (Fig. S4). These results are
consistent with previous studies and shows that trehalose
counteracts docetaxel-induced apoptosis.
Opposite role of trehalose and rapamycin on docetaxel-
induced cell death in PC3 cells
Since trehalose and rapamycin exert different role on
the intrinsic apoptotic pathway triggered by docetaxel, we
evaluated whether these autophagy inducers have a dif-
ferent effect on docetaxel-induced cytotoxicity. We found
that trehalose treatment partially reduced docetaxel-
induced cell death in PC3 cells, but this protective effect
was abolished by 3-MA, as well as by the silencing of the
ATG5 gene, which is involved in autophagy activation
(Fig. 8a). Rapamycin added at doses ranging from 10 to
100 nM to docetaxel-treated cells was found active to
signiﬁcantly reduce cell viability but only at the highest
dose (Fig. 8b) when compared to docetaxel-treated cells.
Autophagy inhibition via 3-MA, or genetically by ATG5
downregulation with a speciﬁc siRNA, abrogated the
effect of rapamycin and the adverse effects of the com-
bined treatment with rapamycin and docetaxel on cell
viability (Fig. 8c). Thus, trehalose-induced mitophagy
exerts a cytoprotective effect against chemotherapy, while
rapamycin-induced autophagy activates a type of caspase-
independent cell death, which synergizes with the apop-
totic death induced by docetaxel.
Finally, we tested whether docetaxel, trehalose or
rapamycin alone or in combination modify the
same parameters in LNCaP and DU145 cells. In LNCaP
cells, we observed the same results obtained in PC3
cells (Fig. 8d, e). Conversely, in DU145 cells, the cyto-
toxicity of docetaxel was not reverted by trehalose.
Neither rapamycin increased docetaxel cytotoxic
(Fig. 8f, g).
(see ﬁgure on previous page)
Fig. 3 Trehalose and rapamycin induce autophagy in LNCaP cells, but do not induce autophagy in DU145 cells. a LNCaP cells were treated
with 20, 50,100 mM trehalose or with 10, 50, 100 nM rapamycin for 48 h. MTT assays were performed. Data are mean ± SD of six independent
biological samples (n= 6). Each experiment was repeated three times. Statistical analysis of data was performed by Dunnet test (*p < 0.05 vs. control).
b LNCaP cells were treated for 24, 48 or 72 h with 100mM trehalose or 100 nM rapamycin and WB analysis of LC3 was performed. Detection of
autophagy was analysed by quantiﬁcation of LC3-II/LC3-I ratio. Relative optical density was determined by ImageJ software. Experiments were
performed independently three times and a representative blot is shown. c LNCaP cells were treated for 24, 48 or 72 h with 100 mM trehalose or 100
nM rapamycin and WB analysis of p62 was performed. Tubulin was used as loading control. Bar graph represents mean optical density ± SD of p62
levels. The experiments were performed independently three times. Statistical analysis was performed by one-way ANOVA with Bonferroni post-test
(*p < 0.05). d DU145 cells were treated with 20, 50,100mM trehalose or with 10, 50, 100 nM rapamycin for 48 h. MTT assays were performed. Data are
mean ± SD of six independent biological samples (n= 6). Each experiment was repeated three times. Statistical analysis of data was performed by
Dunnet test (*p < 0.05 vs. control). e DU145 cells were treated for 48 or 72 h with 100mM trehalose or 100 nM rapamycin. WB analysis of LC3 was
performed. Protein extract of PC3 cells treated with 100mM trehalose for 48 h was utilized as a positive control, tubulin was used as loading control.
f DU145 cells were treated for 48 or 72 h with 100mM trehalose or 100 nM rapamycin. WB analysis of p62 was performed. Tubulin was used as
loading control. Bar graph represents mean optical density ± SD of p62 levels. The experiments were performed independently three times. Statistical
analysis was performed by one-way ANOVA with Bonferroni post-test.
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Fig. 4 Docetaxel induces apoptosis, autophagy and mitochondrial ﬁssion in PC3 cells. a MTT viability assay was performed on PC3 cells treated
with 1, 10, 20, 50, 100 nM docetaxel for 48 h. Six independent biological samples for each condition were analysed (n= 6), bar graph represents the
mean relative cell viability ± SD. Statistical analysis was performed using Dunnet test (*p < 0.05 vs. control). b PC3 cells were treated with 20 nM
docetaxel for 24, 48 or 72 h. WB shows the levels of cleaved-caspase-3 (c-caspase-3), 35 μg of protein extract was loaded. Experiments were
performed independently three times and a representative blot is shown. c LC3 mRNA expression levels were analysed by RT-qPCR after treatment
with 20 nM docetaxel for 48 or 72 h. Data were normalized to the amount of RplP0 mRNA. Data are mean ± SD of four independent biological
samples (n= 4). Statistical analysis was performed using Student’s t test (*p < 0.05 vs. control 48 h, **p < 0.01 vs. control 72 h). d To analyse the
autophagy activation, cells were treated with 20 nM docetaxel for 24, 48 or 72 h. LC3 expression was evaluated by WB. Quantiﬁcation of LC3-II/LC3-I
ratio was performed by the measure of bands optical density by ImageJ software. The experiments were performed independently three times and a
representative blot is shown. e IF shows LC3 distribution in PC3 cells after 48 h of 20 nM docetaxel treatment. Nuclei were stained with DAPI. Scale
bar, 20 μm. f p62 mRNA expression levels were detected by RT-qPCR after treatment with 20 nM docetaxel for 48 or 72 h. Data were normalized to
the amount of RplP0 mRNA. Data are mean ± SD of four independent biological samples (n= 4). Statistical analysis was performed using Student’s t
test (*p < 0.01 vs. control 48 h, **p < 0.01 vs. control 72 h). g WB shows p62 protein expression levels after treatment with docetaxel 20 nM for 48 or
72 h. Three independent experiments were analysed; bar graph represents p62/tubulin mean optic density ± SD. Statistical analysis was performed by
Student’s t test. h p62 IF analysis was done after 48 h of docetaxel treatment. Nuclei were stained with DAPI. Scale bar, 20 μm. i MTT assay performed
on PC3 cells after 48 h of treatment with 20 nM docetaxel alone or in presence of 1 mM 3-MA added 1 h before docetaxel treatment. Six independent
biological samples for each condition were analysed (n= 6), bar graph represents the mean relative cell viability ± SD. Statistical analysis was
performed using one-way ANOVA followed by Bonferroni post-test (*p < 0.05). j pDsred2-mito ﬂuorescence microscopy analysis shows mitochondrial
distribution and localization in PC3 cells treated with 100mM trehalose, 100 nM rapamycin and/or 20 nM docetaxel (48 h). Scale bar, 20 μm
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A rescue experiment was performed in DU145 cells in
order to evaluate whether these cells may become sensi-
tive to trehalose when autophagy is restored. We thus
overexpressed the ATG5 protein in DU145 cells (which
are characterized by the absence of this proautophagic
factor) and found that trehalose signiﬁcantly reduced the
cytotoxic effect of docetaxel in these cells (Fig. S5). This
conﬁrms that autophagy mediates the action of trehalose
even in DU145 cells when this pathway is “re-activated”.
Discussion
Development of chemoresistance is one of the major
problem in cancer therapy, in which autophagy may play a
role. It is still controversial whether autophagy kills cancer
cells or sustains their survival under stressful conditions
as chemotherapy or radiation therapy. Many studies argue
that autophagy is implicated in cancer cells resistance to
chemotherapy and thus autophagy inhibition could
improve the anticancer outcome by resensitizing cancer
cells to chemotherapy17,18,59. Nevertheless, other reports
suggest that autophagy enhances the effect of che-
motherapy and radiotherapy inducing cell death60,61.
Here, we determined if different autophagy activators,
trehalose and rapamycin, modulate docetaxel-induced
toxicity in CRPC cell lines. We demonstrated that in PC3
cells trehalose induces autophagy by activating LC3 and
p62 autophagy markers. Notably, LC3 and p62 degrada-
tion were lower than their synthesis. In PC3 cells, also
rapamycin induced LC3 RNA and protein levels, but
puncta induction was evident after autophagy ﬂux
blockage. Rapamycin enhanced p62 expression, but
reduced p62 protein levels, a phenomenon associated to
an active autophagy. Therefore, rapamycin induces
autophagy in PC3 cells as previously shown50–52,62.
Conversely, while the effects of trehalose and rapamycin
were replicated in LNCaP cells, the inducers did not
activate autophagy in DU145 cells, which are refractory to
autophagy activation because of the lack of full-length
ATG545. However, when autophagy was “re-activated” by
transfecting the ATG5 protein, we found that these cells
became sensitive to the trehalose effects on docetaxel-
induced cell death.
In PC3 cells docetaxel activates caspase-3 cleavage,
suggesting that apoptosis is centrally involved in
docetaxel-induced toxicity in PC3 cells63,64. The role of
Fig. 5 Trehalose and rapamycin differently modify LC3/
mitochondria and p62/mitochondria colocalization in docetaxel-
treated PC3 cells. a PC3 cells were treated for 48 h with 100mM
trehalose or 100 nM rapamycin and/or 20 nM docetaxel. The cells
were stained with 250 nM MitoTracker Orange for 30 min to stain
the mitochondria and then ﬁxed with paraformaldehyde. IF shows
LC3 and mitochondria localization. Nuclei were stained with DAPI.
b PC3 cells were treated for 48 h with 100mM trehalose or 100 nM
rapamycin and/or 20 nM docetaxel. The cells were stained with
250 nM MitoTracker Orange for 30 min to stain the mitochondria and
then ﬁxed with paraformaldehyde. IF shows p62 and mitochondria
localization. Nuclei were stained with DAPI. Images were acquired by
Zeiss Axiovert 200 microscope equipped with ×63/1.4 objective lens
linked to a Coolsnap Es CCD camera (Ropper Scientiﬁc-Trenton, NJ,
USA), scale bar 20 μm
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autophagy in this context is unclear. Our studies
demonstrate that docetaxel induces autophagy according
to Zhang et al.65, but the inhibition of this process does
not alter the sensitivity to docetaxel, in line with studies
showing that autophagy does not mediate docetaxel
toxicity or resistance66. On the other hand our results
diverge from a previous report suggesting that 3-MA
alters docetaxel-induced toxicity63, then this aspect is still
controversial.
We also found a direct involvement of the mitochon-
drial quality control system. Mitochondria are crucial to
modulate the cross-talk between autophagy and apopto-
sis, and regulate cell death or survival decision67,68.
Studying mitochondria distribution we demonstrated that
docetaxel, trehalose and rapamycin induce mitochondria
ﬁssion, which is mediated by several biological phenom-
ena, including apoptosis and autophagy69,70. Here,
mitochondrial ﬁssion correlated with the apoptosis acti-
vation by docetaxel and with autophagy activation by
trehalose and rapamycin. The combined treatments of
docetaxel with the autophagy inducers demonstrated a
clear different spatial redistribution of mitochondria: the
combination of trehalose and docetaxel determined the
perinuclear mitochondrial aggregation, the combination
of rapamycin with docetaxel resulted in a widespread
cytoplasmic distribution of mitochondria.
In mammalian cancer cells, these processes are differ-
entially associated to mitochondrial turnover. Indeed,
mitochondria damaged by different type of stresses
undergo a selective autophagy, named mitophagy56, in
which membrane potential loss induces mitochondria
ubiquitination and p62 recruitment for their insertion
into autophagosomes and perinuclear region localization
into mito-aggresomes71,72. This step precedes their
Fig. 6 Trehalose and rapamycin differently modify mitochondria/lysosomes colocalization in docetaxel-treated PC3 cells. PC3 cells were
treated for 48 h with 100 mM trehalose or 100 nM rapamycin and/or 20 nM docetaxel. The cells were stained with 250 nM MitoTracker Orange for 30
min to stain the mitochondria. Lysosomal staining was performed with 50 nM LysoTracker Green for 45 min. Images were acquired with ×63/1.4
objective lens linked to a Coolsnap Es CCD camera (Ropper Scientiﬁc-Trenton, NJ, USA). Scale bar 20 μm. Graphs in the right panel show green and
red ﬂuorescence intensity of highlighted dot
Cristofani et al. Cell Death and Disease  (2018) 9:889 Page 11 of 19
Ofﬁcial journal of the Cell Death Differentiation Association
Fig. 7 (See legend on next page.)
Cristofani et al. Cell Death and Disease  (2018) 9:889 Page 12 of 19
Ofﬁcial journal of the Cell Death Differentiation Association
lysosomal degradation. In our experiments, trehalose and
docetaxel administered together trigger the initial phases
of mitophagy, by inducing a marked relocalization of
mitochondria around nuclear envelope, generating mito-
aggresomes-like structures. These structures are absent in
rapamycin- and docetaxel-treated cells. Mitophagy
induction after trehalose and docetaxel exposure is also
corroborated by the mitochondria colocalization with
LC3- and p62-positive autophagosomes in docetaxel-
treated cells. Mitochondria accumulation into autopha-
gosomes was not induced by rapamycin (even in combi-
nation with docetaxel), while trehalose alone increased
autophago-lysosomes formation causing aggregated
mitochondria accumulation into lysosomes. Thus, treha-
lose induces mitophagy, while rapamycin only activated
autophagy with large cytoplasmic vacuoles formation, but
not mitophagy. Interestingly, trehalose does not induce
apoptosis per se, but it counteracts docetaxel-triggered
apoptosis, also enhancing the removal of damaged mito-
chondria by mitophagy. This maintains the pool of
mitochondria poorly sensitive to apoptotic stimuli, since
mitochondria accumulated into autophago-lysosomes
cannot release cytochrome c to trigger apoptosis.
Our data parallel previous studies on neurodegenerative
diseases, where trehalose induces mitophagy in tau
pathology preventing cytochrome c release from damaged
mitochondria and exerting a protective antiapoptotic role
against the disease27. This may be viewed as a Janus effect
of trehalose in human diseases. Indeed, for cancer treat-
ment, this effect represents the other face of the coin,
since trehalose protection against cytotoxic stresses
induced by chemotherapy attenuated its efﬁciency, as
demonstrated by the reduction of docetaxel-induced
cytotoxicity in PC3 cells exposed to trehalose. Notably,
rapamycin did not activate apoptosis per se and did not
modify the proapoptotic activity of docetaxel, but poten-
tiated the anticancer effects induced by docetaxel on PC3
cells. Other studies showed that rapamycin enhances
docetaxel40 and cisplatin41 cytotoxicity in PC3 cells.
Our observations explain data collected in melanoma
cells, in which trehalose counteracts cisplatin-mediated
apoptosis, whereas the CCI-779 rapamycin analogue is
ineffective73.
Collectively, the results obtained lead to hypothize
that trehalose-induced mitophagy represents a crucial
cellular survival response involved in chemotherapy
resistance. Alternatively, activation of autophagy
mediated by rapamycin is a phenomenon that causes
cell death and enhances the effect of chemotherapy (Fig.
S6).
In conclusion, our ﬁndings clarify that mitophagy is a
key mechanism in docetaxel-resistance in CRPC and
focus that the molecular mechanisms of autophagy acti-
vation are crucial for the therapeutic use of combination
therapies.
Materials and methods
Antibodies and reagents
Rabbit anti-LC3 (L8918), mouse anti-alpha-tubulin
(T6199) and mouse anti-FLAG® clone M2 (F1804) were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Rabbit anti-SQSTM1/p62 (PA5-20839) was from Ther-
moFisher Scientiﬁc (Waltham, MA, USA). Rabbit anti-
procaspase-3 (#9665), rabbit anti-cleaved-caspase-3 (Asp-
175, clone 5A1E) (#9664), mouse anti-procaspase-9
(#9508), rabbit anti-PARP (#9542), rabbit anti-cleaved-
PARP (#5625), rabbit anti-Atg5 (#12964) were from Cell
Signaling (Danvers, MA, USA). Mouse anti-cytochrome c
(7H8) (sc-13560) was from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Mouse anti-GFP (Ab1218) was
from Abcam (Cambridge, UK). Rabbit and mouse
horseradish-peroxidase-conjugated secondary antibody
were from Cell Signaling. FITC-conjugated secondary
antibody Alexa Fluor 488, MitoTracker Orange CMTM
Ros (mitochondrial selective dye) (M7510) and the
LysoTracker Green DND-26 (lysosomal selective dye)
(L7526) were acquired from Molecular Probes (Thermo-
Fisher Scientiﬁc). Trehalose (T0167), rapamycin (R0395),
chloroquine (CQ) (C6628), ammonium chloride (NH4Cl)
and docetaxel were purchased from Sigma-Aldrich. 3-MA
(S2767) was obtained from Selleckchem (Munich,
Germany).
(see ﬁgure on previous page)
Fig. 7 Trehalose and rapamycin differently counteract docetaxel-induced apoptosis in PC3 cells. a Mitochondrial localization of cytochrome c
was evaluated by IF. Cells were treated with 20 nM docetaxel and/or 100 mM trehalose. After 48 h, the cells were incubated for 30 min with 250 nM
MitoTracker Orange, ﬁxed and stained with cytochrome c antibody followed by FITC secondary antibody. Images were acquired with ×63/1.4
objective lens linked to a Coolsnap Es CCD camera (Ropper Scientiﬁc-Trenton, NJ, USA). Scale bar 20 μm. b WB shows caspase-9, caspase-3 and PARP
and their cleaved active form after 48 h of treatment with 20 nM docetaxel and/or 100 mM trehalose. Each experiment was repeated three times and
representative blots are shown. c Cells were treated with 20 nM docetaxel and/or 100 nM rapamycin. The mitochondrial localization of cytochrome c
was evaluated by IF analysis as described in a. d The cells were treated with 20 nM docetaxel and/or 100 nM rapamycin for 48 h. The analysis of
apoptotic-related proteins was conducted as described in b. e PC3 cells were treated with 20 nM docetaxel, 100 mM trehalose and/or 100 nM
rapamycin. After 24 h of the treatment the cells were labelled with Annexin V-FITC and PI. Dot-plots represent ﬂow cytometry analysis of 10,000
events. Experiment was repeated three times and representative plots are shown
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Plasmids and siRNA
pcDNA5/TO-polyQ plasmid was used to express polyQ
containing protein, it was constructed by cloning the
sequence of N-term polyQ tract of Huntingtin into Hin-
dIII and NotI sites of pcDNA5/TO (Life Technologies,
V103320). This sequence contains an N-term FLAG tag.
pCI-neo-hApg5-HA was a gift from Noboru Mizushima
(Addgene plasmid # 22948). It was used to express wild-
type ATG5 gene in DU145 cells74.
The pEGFPN1 (Clontech, U55762) plasmid was used to
evaluate transfection efﬁciency in experiments involving
transient transfections.
To silence endogenous ATG5 expression we used
negative control (NC) siRNA (#6568) and ATG5 siRNA I
(#6345) obtained from Cell Signaling (#6345).
Cell culture and treatments
Human PC cell lines, LNCaP, PC3 and DU145, were
purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA). The cells were authenti-
cated using Short Tandem Repeat analysis as described in
ANSI Standard (ASN-0002) by ATCC Standards Devel-
opment Organization (SDO). LNCaP, PC3 and
DU145 cells were maintained in RPMI-1640 medium
(EuroClone, Milano, Italy) supplemented with 10% (PC3)
and 5% (LNCaP and DU145) fetal bovine serum (FBS)
(Gibco, ThermoFisher Scientiﬁc), glutamine (1 mmol/l)
and antibiotics (100 IU/ml penicillin G) and cultured at
37 °C in humidiﬁed atmosphere of 5% CO2.
Cell viability assay
LNCaP, PC3 and DU145 cells were plated at the density
of 3×104 cells/well in 24-well plates. After 48 h cells were
treated with different drugs. At the end of the treatment
the medium was changed with MTT (3-(4,5 dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) solution
(0.5 mg/ml) in RPMI without phenol red and FBS and the
cells were incubated for 30–45min. The precipitate for-
mazan was dissolved with isopropanol. Absorbance at
550 nm was measured by EnSpire Multimode Plate reader
(Perkin Elmer, Milano, Italy).
mRNA expression analysis
PC3 cells were plated at 25×104 cells/well in six-well
multiwell plates, allowed to growth for 48 h and then
treated with 100 mM trehalose or 100 nM rapamycin. 48
or 72 h after treatments, cells were harvested and cen-
trifuged for 5 min at 100 × g at 4 °C; the pellets were
resuspended in 300 μl of TRI Reagent (#T9424; Sigma-
Aldrich) and total RNA isolated according to the manu-
facturer’s instructions. RNA quantiﬁcation was carried
out by absorbance at 260 nm. One microgram of total
RNA was treated with DNAse I (AMPD1; Sigma-Aldrich)
and reverse transcribed into cDNA using the High-
Capacity cDNA Archive Kit (4368813; Life Technologies)
according to the manufacturer’s protocol. All primers for
real-time PCR were designed using the program Primer 3.
The primers were synthesized by MWG Biotech (Ebers-
berg, Germany) with the following sequence: hMAP-LC3-
B 5′-CAG CAT CCA ACC AAA ATC CC-3′ (forward),
5′-GTT GAC ATG GTC AGG TAC AAG-3′ (reverse);
hSQSTM1/p62 5′-CCA GAG AGT TCC AGC ACA GA-
3′ (forward), 5′-CCG ACT CCA TCT GTT CCT CA-3′
(reverse); hRplP0: 5′-GTG GGA GCA GAC AAT GTG
GG-3′ (forward), 5′-TGC GCA TCA TGG TGT TCT
TG-3′ (reverse).
The evaluated efﬁciency of each set of primers was close
to 100% for both target and reference gene. Real-time PCR
was performed using the CFX 96 Real-Time System (Bio-
Rad) in a 10 μl total volume, using the iTaq SYBR Green
Supermix (Bio-Rad), and with 500 nM primers. PCR
cycling conditions were as follows: 94 °C for 10min, 40
(see ﬁgure on previous page)
Fig. 8 Opposite role of trehalose and rapamycin on docetaxel-induced cell death in PC cells. a PC3 cells were treated with 100mM trehalose
and/or 20 nM docetaxel for 48 h. Furthermore, PC3 cells pretreated with or without 1 mM 3-MA for 1 h were exposed to 100mM trehalose and/or 20
nM docetaxel for additional 48 h. Additionally PC3 cells transfected with 50 nM negative control (NC) or ATG5 siRNA were exposed to 100mM
trehalose and/or 20 nM docetaxel for additional 48 h. MTT viability assays were performed. Data are mean ± SD of six independent biological samples
(n= 6). Each experiment was repeated three times. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post-test (*p <
0.05). b PC3 cells were treated with different doses of rapamycin (10, 50, 100 nM) in presence of 20 nM docetaxel (48 h). MTT vitality assay was
performed. Data are mean of six independent biological samples (n= 6). Each experiment was repeated three times. Statistical analysis was
performed by one-way ANOVA followed by Bonferroni post-test (*p < 0.05). c PC3 cells pretreated with or without 1 mM 3-MA for 1 h were exposed
to 100 nM rapamycin and/or 20 nM docetaxel for additional 48 h. Additionally PC3 cells transfected with 50 nM negative control (NC) or ATG5 siRNA
were exposed to 100 nM rapamycin and/or 20 nM docetaxel for additional 48 h. MTT viability assays were performed. Data are mean ± SD of six
independent biological samples (n= 6). Each experiment was repeated three times. Statistical analysis was performed using one-way ANOVA
followed by Bonferroni post-test (*p < 0.05). d LNCaP cells were treated with 1, 2, 10, 20, 50, 100 nM docetaxel. MTT assays were performed. Data are
mean ± SD of six independent biological samples (n= 6). Each experiment was repeated three times. Statistical analysis of data was performed by
Dunnet test (*p < 0.05). e LNCaP cells were treated with trehalose 100mM or rapamycin 100 nM in combination with 2 nM docetaxel for 48 h and
one-way ANOVA followed by Bonferroni post-test for drugs combination experiments (*p < 0.05). f DU145 cells were treated with 1, 10, 20, 50, 100
nM docetaxel. MTT assays were performed. Data are mean ± SD of six independent biological samples (n= 6). Each experiment was repeated three
times. Statistical analysis of data was performed by Dunnet test (*p < 0.05). g DU145 cells were treated with trehalose 100mM or rapamycin 100 nM
in combination with 20 nM docetaxel for 48 h and one-way ANOVA followed by Bonferroni post-test for drugs combination experiments (*p < 0.05)
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cycles at 94 °C for 15 s and 60 °C for 1min. Melting curve
analysis was performed at the end of each PCR assay as a
control for speciﬁcity. Data were analysed and expressed as
previously described75–77. Values were normalized to those
of RplP0. All statistics were performed with ΔCt values.
Western blotting
For WB studies LNCaP, PC3 and DU145 cells were
seeded at 3×105 cells/plate in 10 cm dishes. After 48 h,
cells were treated with drugs and at the end of experi-
ments they were washed with PBS and lysed with RIPA
buffer (0.05 mol/l Tris HCl pH 7.7, 0.15 mol/l NaCl, 0.8%
SDS, 10 mmol/l EDTA, 100 μM/l NaVO4, 50 mmol/l NaF,
0.3 mmol/l PMSF, 5 mmol/l iodoacetic acid) containing
leupeptin (50 μg/ml), aprotinin (5 μl/ml) and pepstatin
(50 μg/ml). Protein concentration was determined using
BCA protein assay kit (ThermoFisher Scientiﬁc). 15–35
μg of proteins were separated through SDS gel electro-
phoresis and transferred to PVDF (for LC3 analysis) or
nitrocellulose membranes. After blocking, membranes
were incubated at 4 °C overnight using the following
antibodies: anti-LC3 (dilution 1: 2500), anti-SQSTM1/p62
(dilution 1:3000), anti-ATG5 (dilution 1:1000), anti-
procaspase-3 (dilution 1:1000), anti-cleaved-caspase-3
(dilution 1:500), anti-procaspase-9 (dilution 1:1000),
anti-PARP (dilution 1:1000), anti-cleaved-PARP (dilution
1:1000), anti-GFP (dilution 1:2000), anti-FLAG® clone M2
(dilution 1:1000). Peroxidase-conjugated secondary anti-
rabbit or anti-mouse antibodies were used for 1 h at room
temperature. The membranes were processed using
enhanced chemiluminescence kit ECL Prime Western
Blotting Detection Reagent (GE Healthcare Life Sciences
Italia, Milano, Italy).
In each WB experiment tubulin expression (dilution
1:2000) was evaluated as a loading control.
Knockdown of ATG5 gene in PC3 cells
PC3 cells were seeded in six-well multiwell plates (for
WB) and 24-well multiwell plates (for MTT assay) for 24
h. Cells were transfected with 50 nM ATG5 siRNA or
negative control siRNA by Lipofectamine 3000 (Life
Technologies−ThermoFischer Scientiﬁc) according to the
manufacturer's instructions. After 24 h medium was
replaced with speciﬁc treatments.
Transient expression of wild-type ATG5 gene in DU145
cells
DU145 cells were seeded in six-well multiwell plates
(for WB) and 24-well multiwell plates (for MTT assay) for
24 h. Cells were transfected with 1 μg of pCI-neo-hApg5-
HA by Lipofectamine 3000 (Life Technologies−Ther-
moFischer Scientiﬁc) according to the manufacturer’s
instructions. After 5 h medium was replaced with speciﬁc
treatments.
Filter retardation assay (FRA)
PC3 cells were plated in six-well multiwell plates at 100
000 cell/well. Twenty-four hours after plating, cells were
transfected with 0.5 μg of pcDNA5/TO-polyQ by Lipo-
fectamine 3000 (Life Technologies−ThermoFischer Sci-
entiﬁc) according to the manufacturer’s instructions.
After 5 h medium was replaced with trehalose 100mM.
Fifty-three hours after transfection, cells were harvested
and centrifuged 5min at 100 × g at 4 °C; the cell pellets
were resuspended in PBS (Sigma-Aldrich, P4417) added
of the protease inhibitor cocktail (Sigma-Aldrich, P8340)
and homogenized using slight sonication to lyse cells and
nuclei. Total proteins were determined with the bicinch-
oninic acid method (BCA assay; Euroclone, EMP014500).
FRA was performed using a Bio-Dot SF Microﬁltration
Apparatus (Bio-Rad). Eight micrograms of the total pro-
teins or 1.5 mg of the total protein were ﬁltered through a
0.2-μm cellulose acetate membrane (Whatman,
100404180). Slot-blots were probed as described for WB
with anti-FLAG® clone M2.
A ChemiDoc XRS System (Bio-Rad, Hercules, Cali-
fornia, USA) was used for the image acquisition of FRA.
Optical density of samples assayed with FRA was detected
and analysed using the Image Lab software (Bio-Rad).
Statistical analyses have been performed using the
relative optical densities deﬁned as the ratio between
optical densities of each independent biological sample
(n= 3) and the mean optical density of control samples.
Immunoﬂuorescence and confocal microscopy
For immunoﬂuorescence studies the cells were seeded
at 3×104 cells/well on polilysine-coated coverslips. After
48 h, cells were treated and ﬁxed with 3% paraf-
ormaldeyde/2% sucrose. Cells were washed with PBS and
permeabilized with 0.1% Triton X-100 in PBS for 20 min
followed by incubation in blocking solution (1% horse
serum in PBS) for 1 h.
Cells were incubated with the following antibodies
diluted in PBS with 3% BSA overnight at 4 °C: anti-LC3
(dilution 1:1000), anti-SQSTM1/p62 (dilution 1:1000),
anti-cytochrome c (dilution 1:200). The cells were washed
with PBS and incubated with secondary antibodies Alexa-
488 for 1 h at room temperature. Nuclei were stained with
DAPI (dilution 1:10 000). Labelled cells were examined
under Zeiss Axiovert 200 microscope (Zeiss, Oberkochen,
Germany) with ×63/1.4 objective lens linked to a Cool-
snap Es CCD camera (Ropper Scientiﬁc-Trenton, NJ,
USA). Confocal microscopy images were acquired with
LSM510 Meta system confocal microscope (Zeiss) and
processed with the Aim 4.2 software (Zeiss).
Live mitochondrial morphology
PC3 cells were grown on coated-polilysine LabTeck
Chamber Slides (Nalgene Nunc). Mitochondria were
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detected by transfecting cells with pDsred2-mito Vector
(Clontech-Takara Bio USA). Transfection was performed
with Lipofectamine 3000 (Life Technologies−Thermo-
Fischer Scientiﬁc) according to the manufacturer’s
instructions. After 5 h, the cells treated with docetaxel,
trehalose or rapamycin alone or in combination for 48 h.
Labelled cells were examined by live microscopy using
Zeiss Axiovert 200 microscope (Zeiss, Oberkochen, Ger-
many) with ×63/1.4 objective lens linked to a Coolsnap Es
CCD camera (Ropper Scientiﬁc-Trenton, NJ, USA).
Mitochondrial and lysosomal staining
PC3 cells were plated at 3×104 cells/well on coated-
polilysine coverslips. After the treatment, they were
stained with 250 nM MitoTracker Orange for 30 min to
stain the mitochondria and with 50 nM LysoTracker
Green for 45min to stain the lysosomes. Then, the cells
were washed with PBS, ﬁxed with paraformaldehyde and
analysed using Zeiss Axiovert 200 microscope or confocal
microscope.
Apoptosis analysis by ﬂow cytometry
Apoptotic cell death was evaluated by ﬂow cytometry
Annexin V/PI double staining. Cells were plated at 2×105
cells/plate in 6 cm dishes and treated with trehalose,
rapamycin and/or docetaxel for 24 h. After treatment,
cells were harvested by trypsin treatment, and resus-
pended in binding buffer and stained with Annexin V
and PI according to the manufacturer’s instructions
(BMS500FI, eBioscience). Immediate analysis of 10 000
event/sample was performed using ﬂow cytometry to
observe ﬂuorescence. Flow cytometry was conducted
using a NovoCyte 3000 (Acea Bioscience, Inc.). Data
were analysed using NovoExpress (Acea Bioscience,
Inc.).
Statistical analysis
All experiments were performed three times and the
results were analysed by unpaired Student’s t test or by
one-way analysis of variance ANOVA, followed by Dun-
net or Bonferroni post-test using the PRISM software
(GraphPad Software, La Jolla, CA, USA).
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